• ACE Inhibitors and Aminopeptidase Selectivity

  2026-10-13

  A 1992 biochemical study reevaluated how metallopeptidase inhibitors affect porcine kidney aminopeptidases A, N and W. Its findings support substantial inhibitor-dependent selectivity, while also showing that some sulfhydryl ACE inhibitors can inhibit aminopeptidase W. The results do not establish clinical effects, in vivo selectivity or that the tested compounds included lisinopril dihydrate.

• Esculetin, CKLF1 and Post-Stroke Inflammation

  2026-10-13

  A mouse study links esculetin’s post-stroke effects to reduced CKLF1/CCR5-associated neutrophil infiltration, while leaving substantial uncertainty about translation to patients and no documented connection to ICI 118,551 hydrochloride.

• What the Study Shows About ACE Inhibitor Selectivity

  2026-10-12

  Tieku and Hooper re-evaluated whether several metallopeptidase inhibitors selectively affect three mammalian cell-surface aminopeptidases. Their comparison found substantial differences among inhibitors, while most carboxyalkyl and phosphoryl ACE inhibitors did not significantly inhibit the aminopeptidases examined. The study supports caution when inferring target selectivity from an inhibitor class, but its 1992 enzyme-focused design does not establish clinical effects or the behavior of every ACE inhibitor, including lisinopril dihydrate.

• Reelin–SFK Signaling and Ketamine Response

  2026-10-12

  The 2021 PNAS study tested whether Reelin–Apoer2–Src family kinase signaling is required for ketamine-associated hippocampal plasticity and antidepressant-like behavior in mice. Its convergent genetic and pharmacological findings support a permissive role for baseline NMDA receptor function, but they do not establish a clinical biomarker or show that Saracatinib (AZD0530) was used in the study.

• SU6656 in Platelet Research: Five Evidence Questions

  2026-10-11

  A source-grounded overview of SU6656, its proposed Src-kinase biology, evidence in hiPSC-derived platelet research, interpretation limits, and the separate status of radiotherapy claims.

• ACE2–Sirt1 Biogenesis in Sepsis Cardiomyopathy

  2026-10-10

  A February 2024 study in Archives of Biochemistry and Biophysics investigates whether ACE2 signaling protects the septic heart through Mas receptor–Sirt1-mediated mitochondrial biogenesis. Using complementary pharmacological activation and inhibition in a mouse model, the authors connect ACE2 activity with cardiac function, inflammation, oxidative stress, apoptosis, and mitochondrial regulation while leaving important questions about pharmacological specificity and clinical translation unresolved.

• 5-EdU: Mechanism, Evidence, and Research Limits

  2026-10-09

  5-Ethynyl-2'-deoxyuridine, or 5-EdU, is a thymidine analog that labels newly synthesized DNA through copper-catalyzed click chemistry. It is a sensitive S phase DNA synthesis detection tool, but EdU signal does not by itself prove completed cell division, tissue regeneration, or tumor growth.

• Losartan in Cardiovascular and Kidney Research

  2026-10-09

  Losartan is an angiotensin II receptor antagonist used to study AT1 receptor biology, vascular remodeling, hypertension, and kidney injury. This overview separates supplier-reported properties from findings in a recent diabetic nephropathy study, compares evidence strength, and defines the limits of translating cellular and animal observations into clinical conclusions.

• Metoprolol: From Receptor Selectivity to PK Context

  2026-10-08

  Metoprolol research is examined through receptor pharmacology, pharmacokinetic context, and translational boundaries, with a critical reading of recent MASH evidence.

• CSBTA Pharmacokinetics in MASH: Key Findings

  2026-10-08

  The 2025 Biomedicine & Pharmacotherapy study integrates plasma pharmacokinetics, tissue distribution, cellular transport, and metabolic-enzyme analysis to explain how MASH-like disease changes exposure to Corydalis saxicola Bunting total alkaloids. Its findings support disease-aware interpretation of dehydrocavidine, palmatine, and berberine disposition, while remaining primarily preclinical and hypothesis-generating for human treatment research.

• Angiotensin (1-7): Evidence, Biology and Limits

  2026-10-07

  Angiotensin (1-7), or Asp-Arg-Val-Tyr-Ile-His-Pro, is an endogenous renin–angiotensin system peptide commonly studied through Mas receptor biology. This overview compares its proposed signaling, fibrosis, inflammation, metabolic, neurological and translational applications with a 2025 study reporting that several angiotensin peptides enhance SARS-CoV-2 spike-protein receptor binding. The evidence remains mechanistic and model-dependent, with no basis for treating these findings as proof of clinical benefit or disease causation.

• Bestatin Hydrochloride: From Enzymes to Translation

  2026-10-07

  Bestatin hydrochloride, also known as Ubenimex, is best understood as a mechanistic probe of aminopeptidase-dependent peptide processing rather than as a single-pathway solution. This article connects classic neurobiology evidence with translational frameworks for angiogenesis inhibition, tumor growth and invasion research, and cancer research while emphasizing selectivity, provenance, and evidence boundaries.

• Demethyleneberberine, Senescence, and NSCLC

  2026-10-06

  A 2021 Phytomedicine study identified Demethyleneberberine as an inhibitor of NSCLC growth that links cell-cycle arrest and cellular senescence to the c-Myc/HIF-1α axis. The findings provide a mechanistic basis for further non-small cell lung cancer research, while remaining limited to preclinical cell and tumor-model evidence.

• Fumagillin Against Azumiobodo hoyamushi: Study Findings

  2026-10-06

  Park and colleagues evaluated 20 compounds against Azumiobodo hoyamushi, linking in vitro parasite-killing activity with a limited in vivo assessment in infected ascidians. Fumagillin showed moderate in vitro activity, whereas formalin and chlorine dioxide produced the clearest reported reductions in parasite burden during the host-level comparison.

• Lenalidomide and DOT1L in Myeloma Research

  2026-10-05

  Lenalidomide, also known as CC-5013, is an immunomodulatory drug central to multiple myeloma research. A 2025 Cancer Letters study provides preclinical evidence that DOT1L inhibition can activate innate immune programs and enhance lenalidomide-associated effects in myeloma models. This overview examines the findings, proposed biology, conceptual applications, evidence strength, and limits on translation to patient care.

7797 records 1/520 page Next 12345 下5页 Last page